Treatment of severe psoriasis with anti-CD25 monoclonal antibodies [6]

Archives of Dermatology

Volumn 136, Issue 5, 2000, Pages 675-676

  Mrowietz, Ulrich ^a   Zhu, Kejian ^b   Christophers, Enno ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY;

ADULT; AGED; CASE REPORT; CELL ACTIVATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LETTER; MALE; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PSORIASIS; SKIN DISEASE; TARGET CELL;

EID: 0034124294     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.136.5.675     Document Type: Letter

References (5)

1. Prinz J, Braun-Falco O, Meurer M, et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis [letter]. Lancet. 1991;338: 320-321.
2. Nicholas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, Reveillard JP. CD4 antibody treatment of severe psoriasis [letter]. Lancet. 1991;338:321.
3. IKQIL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1995;1:442-447.
4. Onrust SV, Wiseman LR. Basiliximab. Drugs. 1999;57:207-213.
5. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 1997;350:1193-1198.